自体脂肪移植因其优势明显，近年来成为整形外科最热门研究领域之一，但成活率低，成活质量差，效果难以预测，仍然是限制其在临床广泛应用的瓶颈。我们以往的研究结果表明，VEGF基因治疗可以明显提高移植脂肪的血管化，提高成活率，而且能促进表达多种血管生成因子的HIF-1α基因治疗效果更强，基因治疗前景虽然很好，但因安全问题短期内难以应用于临床。我们新近的研究发现更有临床应用价值的自体富血小板纤维蛋白（PRF）能明显提高移植脂肪的成活，但具体如何促进脂肪成活的机制不清。从前期研究结果我们推测PRF是通过释放多种细胞因子进行脂肪组织保护的同时促进其血管化这两个策略实现的，本课题拟用分子生物学体内外实验，从抑制细胞凋亡和释放多种血管生成因子促血管化两个方面来研究PRF提高移植脂肪成活的机制，从而推动PRF在脂肪移植的临床广泛应用，同时也为其他缺血性疾病、及组织移植后缺血等的治疗提供新思路。

Because of obvious advantages of autologous fat graft,in recent years, it has become one of the most popular research area in plastic surgery. The key points of autologous fat graft are the low survival rate, poor survival quality, and the undefinite effect.These still limit its widely used in clinical.Our previous research work showed that VEGF gene therapy could significantly improve the angiogenesis of fat graft, and increased the survival rate; HIF - 1 α gene therapy could promote a variety of angiogenesis factors expressing, and could get a better result. The future of gene therapy is good, but it is hard to use in clinical application now because of safety issues. Further, we found that platelet-rich ?brin (PRF), which had more clinical application value, could significantly improve the fat graft survival. But the mechanism of promoting fat graft survival is not clear now. From the earlier study we presume two strategies, on the one hand, PRF release of a variety of angiogenesis factors to promote the neovascularization, on the other hand, PRF protect the grafted fat tissue from ischemia. This research will study molecular biology by in vivo and in vitro experiments,to clarify the two mechanisms.Firstly it can inhibite apoptosis of ECs and ASCs, Secondly it is promoting neovascularization of grafted fat tissue at the same time. The result of this study will not only greatly promote the clinical application of PRF in fat graft, but also provide a new idea for other ischemic diseases, and ischemic grafted tissue.